ENDRA Life Sciences (NDRA)

Executive Summary

ENDRA Life Sciences is a medical diagnostics company focused on the early detection of liver disease through its proprietary TAEUS® technology. TAEUS provides a non-invasive, low-cost method to measure liver fat content, offering a significant advantage over traditional MRI-based approaches, which are expensive and less accessible. The technology is CE-marked for sale in Europe, positioning the company to capture a share of the growing non-alcoholic fatty liver disease (NAFLD) diagnostic market. ENDRA’s solution addresses a critical unmet need, as liver disease often progresses silently, and early detection can prevent severe complications like cirrhosis and hepatocellular carcinoma. Despite its promising technology, ENDRA faces challenges typical of early-stage medtech firms, including limited commercial adoption and the need for additional regulatory approvals. The company has a small market capitalization (~$6 million) and limited revenue, relying on securing partnerships and further regulatory clearances to drive growth. Key upcoming catalysts include potential FDA clearance for the US market and initial commercialization efforts in Europe. If successful, ENDRA could disrupt the liver diagnostics space by providing an affordable, scalable alternative to MRI. However, execution risk remains high, and the stock is speculative. The conviction score is moderate given the technology’s potential and the low current valuation.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) Clearance for TAEUS60% success
• Q3 2026First European Commercial Sales or Partnership70% success
• Q4 2026Publication of Clinical Validation Data80% success